Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1563-1569

  Wang, Li Juan ^a   Han, Su Xia ^a   Bai, E ^a   Zhou, Xia ^a   Li, Meng ^a   Jing, Gui Hua ^a   Zhao, Jing ^a   Yang, An Gang ^b   Zhu, Qing ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AKT; ERK1 2; Ga; Tam resistant breast cancer cells; Tamoxifen

Indexed keywords

ESTROGEN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SMALL INTERFERING RNA; TAMOXIFEN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL COUNT; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; ONCOGENE PROTEIN V-AKT; RNA, SMALL INTERFERING; TAMOXIFEN;

EID: 84874676963     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2245     Document Type: Article

References (40)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467, 1998.
2. Powles TJ, Ashley S, Tidy A, Smith IE and Dowsett M: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99: 283-290, 2007.
3. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300, 2003.
4. Kurebayashi J: Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 56 (Suppl 1): 39-46, 2005.
5. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817-9824, 2001.
6. Gee JM, Robertson JF, Ellis IO and Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254, 2001.
7. Ignatov A, Ignatov T, Weissenborn C, et al: G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128: 457-466, 2011.
8. Miller TW, Balko JM and Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29: 4452-4461, 2011.
9. Brunner N, Frandsen TL, Holst-Hansen C, et al: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53: 3229-3232, 1993.
10. Ignatov A, Ignatov T, Roessner A, Costa SD and Kalinski T: Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123: 87-96, 2010.
11. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004.
12. Benz CC, Scott GK, Sarup JC, et al: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells trans¬fected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1992.
13. Ward A, Balwierz A, Zhang JD, et al: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene: Apr. 16, 2012 (Epub ahead of print).
14. Hurtado A, Holmes KA, Geistlinger TR, et al: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456: 663-666, 2008.
15. Britton DJ, Hutcheson IR, Knowlden JM, et al: Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96: 131-146, 2006.
16. Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717, 2002.
17. Gerits N, Kostenko S, Shiryaev A, Johannessen M and Moens U: Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 20: 1592-1607, 2008.
18. Liu AM, Lo RK, Wong CS, Morris C, Wise H and Wong YH: Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J Biol Chem 281: 35812-35825, 2006.
19. Selever J, Gu G, Lewis MT, et al: Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res 17: 6510-6521, 2011.
20. Schafer JM, Bentrem DJ, Takei H, Gajdos C, Badve S and Jordan VC: A mechanism of drug resistance to tamoxifen in breast cancer. J Steroid Biochem Mol Biol 83: 75-83, 2002.
21. Wiebe VJ, Osborne CK, Fuqua SA and DeGregorio MW: Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 14: 173-188, 1993.
22. Clarke R, Liu MC, Bouker KB, et al: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339, 2003.
23. Schwartz JL, Shajahan AN and Clarke R: The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int J Breast Cancer 2011: 912102, 2011.
24. Zhou C, Zhong Q, Rhodes LV, et al: Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14: R45, 2012.
25. Canney PA, Griffiths T, Latief TN and Priestman TJ: Clinical significance of tamoxifen withdrawal response. Lancet 1: 36, 1987.
26. Howell A, Dodwell DJ, Anderson H and Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3: 611-617, 1992.
27. Banerjee S, Kambhampati S, Haque I and Banerjee SK: Pomegranate sensitizes tamoxifen action in ER-alpha positive breast cancer cells. J Cell Commun Signal 5: 317-324, 2011.
28. Leung E, Kannan N, Krissansen GW, Findlay MP and Baguley BC: MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9: 717-724, 2010.
29. deGraffenried LA, Friedrichs WE, Russell DH, et al: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10: 8059-8067, 2004.
30. Vivacqua A, Bonofiglio D, Recchia AG, et al: The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endome¬trial cancer cells. Mol Endocrinol 20: 631-646, 2006.
31. Carmeci C, Thompson DA, Ring HZ, Francke U and Weigel RJ: Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45: 607-617, 1997.
32. Filardo EJ, Graeber CT, Quinn JA, et al: Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12: 6359-6366, 2006.
33. Li Y, Birnbaumer L and Teng CT: Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol 24: 969-980, 2010.
34. Kleuser B, Malek D, Gust R, Pertz HH and Potteck H: 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracel¬lular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol 74: 1533-1543, 2008.
35. Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68: 826-833, 2008.
36. Hutcheson IR, Knowlden JM, Madden TA, et al: Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81: 81-93, 2003.
37. Zheng B, Lavoie C, Tang TD, et al: Regulation of epidermal growth factor receptor degradation by heterotrimeric Galphas protein. Mol Biol Cell 15: 5538-5550, 2004.
38. Stryjek-Kaminska D, Piiper A and Zeuzem S: Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1-2 proteins in pancreatic acinar membranes. Biochem J 316: 87-91, 1996.
39. Maggiolini M and Picard D: The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 204: 105-114, 2010.
40. Huiart L, Dell'Aniello S and Suissa S: Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 104: 1558-1563, 2011.